menu
    • menu
    [{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTA2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"5","companyTruncated":"Alterome Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ALTA3263","moa":"KRAS ON\/OFF","graph1":"Oncology","graph2":"Phase I","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alterome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Colt Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterome Therapeutics \/ Colt Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Alterome Therapeutics \/ Colt Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Alterome Therapeutics

    Menu

    Alterome Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTA3263

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alterome Doses First Patient in ALTA3263 Phase 1 Study for Solid Tumors

                            Details : ALTA3263 is a non-covalent, oral, highly potent KRAS isoform-selective dual ON/OFF state inhibitor, being investigated in adults with KRAS mutant solid tumors.

                            Product Name : ALTA3263

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : ALTA3263

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTA2618

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alterome Doses First Patient in ALTA2618 Phase 1 Trial for AKT1-Mutant Tumors

                            Details : ALTA2618 is the first allosteric inhibitor of AKT1 E17K and is designed to avoid on-target toxicities associated with the inhibition of AKT family kinases. It is being evaluated for neoplasms.

                            Product Name : ALTA2618

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 30, 2024

                            Lead Product(s) : ALTA2618

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $132.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Alterome Raises $132M to Take Next-Gen Cancer Drugs Aimed at The 'Undruggable' into Clinic

                            Details : Proceeds from fundraising will advance multiple wholly-owned pipeline programs, including a specific AKT1 E17K inhibitor for HR+/HER2-endometrial cancer and triple-negative breast cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $132.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Alterome Therapeutics

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Colt Ventures

                            Deal Size : $100.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies

                            Details : The proceeds will be used to advance Alterome’s pipeline of three next-generation precision oncology programs designed using “The Kraken,” its in-house computational chemistry platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 11, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Colt Ventures

                            Deal Size : $100.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth